Skip to main content
Smart Investors Daily
IR

NASDAQ · IRWD

Ironwood Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$4.70

Down-$0.01 (-0.21%)

Updated Nov 21, 2026, 2:38 AM

SID Score

6.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
598.66M
P/E ratio
7.07
Dividend yield
0.00%
52-week range
$3.02 – $5.00
Volume
3.02M
Avg. volume
2.12M

Price performance · IRWD

IRWD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

IRWD closed at $4.70 after 21 trading sessions, up 35.84% for the selected period.

Last close
$4.70
Period change
+35.84%
Period low
$3.46
Period high
$4.87
Daily close
View OHLC price history
IRWD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$4.655$4.865$4.645$4.703.02M
Nov 19, 2026$4.76$4.79$4.555$4.713.29M
Nov 18, 2026$4.85$4.94$4.7011$4.782.22M
Nov 17, 2026$4.83$4.89$4.765$4.872.82M
Nov 16, 2026$4.81$4.915$4.7609$4.853.11M
Nov 13, 2026$4.84$4.90$4.7601$4.832.81M
Nov 12, 2026$4.83$4.995$4.79$4.853.57M
Nov 11, 2026$4.81$4.93$4.74$4.872.82M
Nov 10, 2026$4.68$4.968$4.65$4.814.59M
Nov 9, 2026$4.50$4.76$4.345$4.685.33M
Nov 6, 2026$4.26$4.44$4.10$4.393.96M
Nov 5, 2026$4.30$4.41$3.84$4.034.99M
Nov 4, 2026$3.61$3.80$3.58$3.772.57M
Nov 3, 2026$3.51$3.57$3.40$3.501.95M
Nov 2, 2026$3.50$3.585$3.4332$3.461.3M
Oct 30, 2026$3.59$3.64$3.45$3.501.47M
Oct 29, 2026$3.65$3.695$3.575$3.621.37M
Oct 28, 2026$3.46$3.63$3.46$3.611.41M
Oct 27, 2026$3.52$3.545$3.45$3.511.66M
Oct 26, 2026$3.49$3.535$3.45$3.501.13M
Oct 23, 2026$3.52$3.536$3.38$3.461.26M

Latest IRWD news

The latest Smart Investors Daily articles mentioning IRWD.

IRWD research

Overview

Company profile and research snapshot.

Company profile

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.80
Implied upside
—
Analysts
—
IRWD recent ratings
DateFirmRatingTarget
Feb 26, 2026CitizensMarket Outperform—
Jan 5, 2026Wells FargoEqual-Weight—
Jan 5, 2026CitizensMarket Outperform—
Nov 11, 2025Wells FargoEqual-Weight—
Apr 15, 2025Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.